Lawyers

Abhinav  Bhalaik

Abhinav Bhalaik

Work Department

Corporate and M&A, Private Equity & Venture Capital

Position

Partner

Career

Abhinav is a key member of the Private Equity, Mergers & Acquisitions and Securities Law practice of the Firm.

He regularly advises various private equity firms, venture and investment funds, corporate strategic investors, multinational corporations, and investment banks on a variety of complex domestic and cross-border mergers and acquisitions, growth capital and early-stage investments. Abhinav also regularly represents portfolio companies of clients with respect to general corporate counselling, transactional matters and shareholder disputes. He has worked across a broad range of sectors (such as healthcare, pharmaceuticals, manufacturing, financial services, fintech, SAAS, edtech, gaming, consumer, agritech and media) and has advised some of the largest domestic and international clients.

Abhinav was previously a partner at SAM & Co., Mumbai. He finished his B.A. LL.B. with honors in corporate law from the National Law University, Jodhpur, India.

Select Professional Experience

Infinx with respect to the equity investment by KKR and Norwest Venture Partners. Zeno Health on its acquisition of Tablt Pharmacy. Pharmacy start-up, Zeno Health on its $25 million Series C funding round. Ind Swift Laboratories Limited and its promoters on the sale of its API and CRAMS businesses for INR 1,650 crores and the sale of the intermediates manufacturing business of Essix Biosciences Limited to India Resurgence Fund. Spendflo Inc. and its promoters on their USD 11 Million Series A Fundraise. Whiteboard Capital Fund on ONWo's seed funding round of USD 1.6 million. Turno on its USD 13.8 million Series A fund raise from B Capital and Quona along with existing investors. Whiteboard Capital Fund on ApnaKlub's Series A fundraise of USD 16 million. Malabar Investments in its INR 100 Crore investment in boAt. MedGenome in its USD 50 million Series D fund raise, led by Novo Holdings. CRED on its USD 140 million Series F funding round led by GIC at a post money valuation of USD 6.4 billion. Malabar Investments on its approx. USD 50 million investment in Games 24x7. Berkshire Hathaway on its potential exit from Paytm as part of the approx. USD 20 billion IPO. Sequoia Capital on its investment in Rebel Foods, Eruditius, Capillary, NextSCM, Bukukas, Scaler and CarDekho. RTP on its various investments, including in Mesh and Rebel Foods. Ind-Swift Laboratories Limited on its agreement to sell its API business for approx. USD 200 million. A 91 on its investment in Indiejewel Fashions, Hector Beverages and La Renon Healthcare. Quona Capital on its investment in Arya Warehousing (approx. USD 21 million). L&T Financial Services on its agreement to raise funds from Apis (approx. USD 100 million). Panacea Biotech Limited on its USD 130 million fund raise from the Rise Fund. Brookfield on its proposed acquisition of Suzlon Energy in a potential IBC scenario. Goldman Sachs on its proposed investment in Manipal for its bid for Fortis (approx. USD 1.2 billion). Sumitomo on its joint venture with the Mahindra group relating to the agro chemical business. Cemex on its proposed acquisition of an Indian listed company (approx. USD 1.5 billion). OMERS on its investment in HDFC (overall transaction value approx. USD 1.1 billion). TPG on its proposed investment in Max Financial for acquisition of IDBI Federal Life Insurance (approx. USD 800 million). Diageo on its acquisition of a majority stake in USL, for an approximate consideration of USD 2.2 billion. Danone on its acquisition of Wockhardt’s nutrition business (approx. USD 300 million). Actis on its various investments and exits in India, including its exit from National Stock Exchange of India Limited and Paras Pharmaceuticals Limited to Reckitt Benckiser for approx. USD 726 million.

Memberships

Bar Council of Maharashtra & Goa.

Mentions

India

Corporate and M&A

City focus: Mumbai • India

TMT